Home » News » 01/06 » Leo Pharma gets FDA psoriasis treatment approval

Leo Pharma gets FDA psoriasis treatment approval

Date published: 11/01/2006

Leo Pharma and Warner Chilcott have received approval from the US Food and Drug Administration (FDA) for the psoriasis treatment Taclonex (Dovobet).

The New Drug Application (NDA) for Taclonex was submitted to the FDA in March 2005 as a treatment for of psoriasis vulgaris in adults. The ointment contains a combination of calcipotriene 0.005 per cent and betamethasone dipropionate 0.064 per cent.

Warner Chilcott CEO Roger Boissonneault said: "Taclonex presents an exciting proposition for the treatment of psoriasis in the U.S., and we are preparing for its launch with great anticipation." Warner Chilcott is the exclusive licensee of Taclonex in the US and the company expects to launch the drug in the first half of this year

Psoriasis, which has no cure, affects around 2 per cent of the UK population and the condition involves the overproduction of skin cells.

© Adfero Ltd

Disclaimer

AllAboutMedicalSales excludes any warranty, express or implied, as to the quality, accuracy, timeliness, completeness or fitness for a particular purpose of this briefing. AllAboutMedicalSales will not be liable for any claims, penalties, losses, damages, costs, or expenses arising from the use of or inability to use this briefing or from any unauthorised access to or alteration of the Briefing. AllAboutMedicalSales makes no warranty that the contents of this briefing are compatible with all computer systems and browsers.